The Drug-to-Antibody Ratio (DAR) is the most important quality attribute of ADC drugs because it determines the “payload” that can be delivered to tumors, directly impacting safety and efficacy. Here, we […]
Driven by increasingly mature technologies, ADC payloads have undergone three generations of innovation. In the first generation of ADC drugs, traditional chemotherapy agents such as methotrexate, vincristine, and doxorubicin were used […]
In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the […]
The popularity of thiol coupling in ADC preparation can be attributed to three factors: It is essential to note that a reduction step is always required before coupling to release […]
Antibody conjugated drug (ADC) is a relatively complex molecule that connects a targeted antibody with a cytotoxic payload through a chemical linker. In recent years, people have gradually deepened their research on payload and […]
Antibody drug conjugates (ADCs) are multi-domain molecules composed of monoclonal antibodies, linkers and small molecule cytotoxins. ADCs specifically bind target antigens highly expressed on the surface of tumor cells through monoclonal antibodies, enter […]
Antibody drug conjugates (ADCs) are a new class of biopharmaceuticals that use monoclonal antibodies to target tumor cells to deliver potent cytotoxic drugs. So far, a total of 15 ADC drugs […]
Breast cancer is the leading cause of death among women worldwide. When breast cancer spreads to other parts of the body, the prognosis is poor. Currently, there is no treatment […]
Among the first-generation ADC drugs, traditional chemotherapy drugs such as methotrexate, vinblastine, and doxorubicin were used as cytotoxic payloads. However, due to insufficient cytotoxicity and selectivity against tumor cells, the first-generation […]
The concept of ADCs was first proposed by Nobel Prize winner Paul Ehrlich in 1913. But it was not until 1975, when hybridoma technology began to be used to produce monoclonal […]